Subclinical detection of diabetic cardiomyopathy with MicroRNAs: Challenges and perspectives

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  León, Luis E ^a   Rani, Sweta ^b   Fernandez, Mauricio ^c   Larico, Martín ^c   Calligaris, Sebastián D ^a  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; MICRORNA; NATRIURETIC FACTOR; BIOLOGICAL MARKER;

CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; DIABETIC CARDIOMYOPATHIES; EARLY DIAGNOSIS; GENETICS; METABOLISM;

BIOMARKERS; DIABETIC CARDIOMYOPATHIES; EARLY DIAGNOSIS; HUMANS; MICRORNAS;

EID: 84953331062     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/6143129     Document Type: Review

References (87)

1. IDF, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 6th edition, 2014.
2. M. C. Blendea, S. I. McFarlane, E. R. Isenovic, G. Gick, and J. R. Sowers, "Heart disease in diabetic patients," Current Diabetes Reports, vol. 3, no. 3, pp. 223-229, 2003.
3. A. I. Vinik and D. Ziegler, "Diabetic cardiovascular autonomic neuropathy," Circulation, vol. 115, no. 3, pp. 387-397, 2007.
4. H. Bugger and C. Bode, "The vulnerable myocardium. Diabetic cardiomyopathy,"Hamostaseologie, vol. 35, no. 1, pp. 17-24, 2015.
5. A. M. From, C. L. Leibson, F. Bursi, et al., "Diabetes in heart failure: prevalence and impact on outcome in the population," The American Journal of Medicine, vol. 119, no. 7, pp. 591-599, 2006.
6. A. M. Shah, H. Uno, L. Køber, et al., "The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction," European Journal of Heart Failure, vol. 12, no. 11, pp. 1229-1237, 2010.
7. S. Rubler, J. Dlugash, Y. Z. Yuceoglu, T. Kumral, A. W. Branwood, and A. Grishman, "New type of cardiomyopathy associated with diabetic glomerulosclerosis," The American Journal of Cardiology, vol. 30, no. 6, pp. 595-602, 1972.
8. H. Bugger and E. D. Abel, "Rodentmodels of diabetic cardiomyopathy," DiseaseModels&Mechanisms, vol. 2, no. 9-10, pp. 454-466, 2009.
9. H. Bugger and E. D. Abel, "Molecular mechanisms of diabetic cardiomyopathy," Diabetologia, vol. 57, no. 4, pp. 660-671, 2014.
10. T. Miki, S. Yuda, H. Kouzu, and T. Miura, "Diabetic cardiomyopathy: pathophysiology and clinical features," Heart Failure Reviews, vol. 18, no. 2, pp. 149-166, 2013.
11. A. Dei Cas, V. Spigoni, V. Ridolfi, and M. Metra, "Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach," Endocrine, Metabolic & Immune Disorders-Drug Targets, vol. 13, no. 1, pp. 38-50, 2013.
12. S. Boudina and E. D. Abel, "Diabetic cardiomyopathy, causes and effects," Reviews in Endocrine & Metabolic Disorders, vol. 11, no. 1, pp. 31-39, 2010.
13. V. Chavali, S. C. Tyagi, and P. K. Mishra, "Predictors and prevention of diabetic cardiomyopathy," Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 6, pp. 151-160, 2013.
14. C. Teupe and C. Rosak, "Diabetic cardiomyopathy and diastolic heart failure-difficulties with relaxation," Diabetes Research and Clinical Practice, vol. 97, no. 2, pp. 185-194, 2012.
15. J.-W. Ha, H.-C. Lee, E.-S. Kang, et al., "Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography," Heart, vol. 93, no. 12, pp. 1571-1576, 2007.
16. J. M. McGavock, I. Lingvay, I. Zib, et al., "Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study," Circulation, vol. 116, no. 10, pp. 1170-1175, 2007.
17. P. Shah, B. G. Choi, and R. Mazhari, "Positron emission tomography for the evaluation and treatment of cardiomyopathy," Annals of the New York Academy of Sciences, vol. 1228, no. 1, pp. 137-149, 2011.
18. S. Romano, M. DiMauro, S. Fratini, et al., "Earlydiagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides," Cardiovascular Diabetology, vol. 9, article 89, 2010.
19. K. Rahimi, D. Bennett, N. Conrad, et al., "Risk prediction in patients with heart failure: a systematic review and analysis," JACC: Heart Failure, vol. 2, no. 5, pp. 440-446, 2014.
20. A. Palazzuoli, S. Masson, C. Ronco, and A. Maisel, "Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin," Heart Failure Reviews, vol. 19, no. 2, pp. 267-284, 2014.
21. E. C. Lai, "Two decades of miRNA biology: lessons and challenges," RNA, vol. 21, no. 4, pp. 675-677, 2015.
22. M. Asrih and S. Steffens, "Emerging role of epigenetics and miRNA in diabetic cardiomyopathy," Cardiovascular Pathology, vol. 22, no. 2, pp. 117-125, 2013.
23. V. K. Cortessis, D. C. Thomas, A. Joan Levine, et al., "Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships," Human Genetics, vol. 131, no. 10, pp. 1565-1589, 2012.
24. V. Ambros, "The functions of animal microRNAs," Nature, vol. 431, no. 7006, pp. 350-355, 2004.
25. W. Filipowicz, S. N. Bhattacharyya, and N. Sonenberg, "Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?" Nature Reviews Genetics, vol. 9, no. 2, pp. 102-114, 2008.
26. H. Lu, R. J. Buchan, and S. A. Cook, "MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism," Cardiovascular Research, vol. 86, no. 3, pp. 410-420, 2010.
27. H. El Azzouzi, S. Leptidis, E. Dirkx, et al., "The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation," Cell Metabolism, vol. 18, no. 3, pp. 341-354, 2013.
28. Y. Duan, B. Zhou, H. Su, Y. Liu, and C. Du, "MiR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300," Experimental Cell Research, vol. 319, no. 3, pp. 173-184, 2013.
29. B. Feng, S. Chen, B. George, Q. Feng, and S. Chakrabarti, "miR133a regulates cardiomyocyte hypertrophy in diabetes," Diabetes/Metabolism Research and Reviews, vol. 26, no. 1, pp. 40-49, 2010.
30. E. Shen, X. Diao, X. Wang, R. Chen, and B. Hu, "MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy," The American Journal of Pathology, vol. 179, no. 2, pp. 639-650, 2011.
31. X. Diao, E. Shen, X. Wang, and B. Hu, "Differentially expressed microRNAs and their target genes in the hearts of streptozotocin-induced diabetic mice," Molecular Medicine Reports, vol. 4, no. 4, pp. 633-640, 2011.
32. F. Zhao, B. Li, Y.-Z. Wei, et al., "MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes," Journal of Huazhong University of Science and Technology-Medical Science, vol. 33, no. 6, pp. 834-839, 2013.
33. X.-Y. Yu, Y.-H. Song, Y.-J. Geng, et al., "Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1," Biochemical and Biophysical Research Communications, vol. 376, no. 3, pp. 548-552, 2008.
34. S. S. Yildirim, D. Akman, D. Catalucci, and B. Turan, "Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1," Cell Biochemistry and Biophysics, vol. 67, no. 3, pp. 1397-1408, 2013.
35. X. Li, N. Du, Q. Zhang, et al., "MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy," Cell Death and Disease, vol. 5, article e1479, 2014.
36. X. H. Wang, R. Z. Qian, W. Zhang, S. F. Chen, H. M. Jin, and R. M. Hu, "MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationshipwith insulin-like growth factor-1 in type 2 diabetic rats," Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 2, pp. 181-188, 2009.
37. S. K. Panguluri, J. Tur, K. C. Chapalamadugu, C. Katnik, J. Cuevas, and S. M. Tipparaju, "MicroRNA-301a mediated regulation of Kv4. 2 in diabetes: identification of key modulators," PLoS ONE, vol. 8, no. 4, article e60545, 2013.
38. W. A. Baseler, D. Thapa, R. Jagannathan, E. R. Dabkowski, T. L. Croston, and J. M. Hollander, "miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart,"The American Journal of Physiology-Cell Physiology, vol. 303, no. 12, pp. C1244-C1251, 2012.
39. Y. Kuwabara, T. Horie, O. Baba, et al., "MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat dietinduced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway," Circulation Research, vol. 116, no. 2, pp. 279-288, 2015.
40. S. Ong and J. C. Wu, "Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration," Circulation Research, vol. 117, no. 1, pp. 7-9, 2015.
41. Z. A. Malik, K. S. Kott, A. J. Poe, et al., "Cardiac myocyte exosomes: stability, HSP60, and proteomics," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 7, pp. H954-H965, 2013.
42. N. Genneback, U. Hellman, L. Malm, et al., "Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes," Journal of Extracellular Vesicles, vol. 2, 2013.
43. A. Waldenström, N. Genneback, U. Hellman, and G. Ronquist, "Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells," PLoS ONE, vol. 7, no. 4, Article ID e34653, 2012.
44. C. Bang, S. Batkai, S. Dangwal, et al., "Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy,"The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2136-2146, 2014.
45. S. Rani, "MicroRNA profiling of exosomes isolated from biofluids and conditioned media," Methods in Molecular Biology, vol. 1182, pp. 131-144, 2014.
46. K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley, "MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins," Nature Cell Biology, vol. 13, no. 4, pp. 423-435, 2011.
47. F. Spillmann, S. van Linthout, and C. Tschöpe, "Cardiac effects of HDL and its components on diabetic cardiomyopathy," Endocrine, Metabolic & Immune Disorders-Drug Targets, vol. 12, no. 2, pp. 132-147, 2012.
48. J. F. Aranda, J. Madrigal-Matute, N. Rotllan, and C. Fernandez-Hernando, "MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases," Free Radical Biology and Medicine, vol. 64, pp. 31-39, 2013.
49. G. Meister, "Argonaute proteins: functional insights and emerging roles," Nature Reviews Genetics, vol. 14, no. 7, pp. 447-459, 2013.
50. J. D. Arroyo, J. R. Chevillet, E. M. Kroh, et al., "Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 5003-5008, 2011.
51. R. C. Friedman, K. K.-H. Farh, C. B. Burge, and D. P. Bartel, "Most mammalian mRNAs are conserved targets of microRNAs," Genome Research, vol. 19, no. 1, pp. 92-105, 2009.
52. J. P. Mehta, "Sequencing small RNA: introduction and data analysis fundamentals,"Methods inMolecular Biology, vol. 1182, pp. 93-103, 2014.
53. P. Alexiou, M. Maragkakis, G. L. Papadopoulos, V. A. Simmosis, L. Zhang, and A. G. Hatzigeorgiou, "TheDIANA-mirExTraweb server: fromgene expression data to microRNA function," PLoS ONE, vol. 5, no. 2, Article ID e9171, 2010.
54. M. Kunz, K. Xiao, C. Liang, et al., "Bioinformatics of cardiovascular miRNA biology," Journal of Molecular and Cellular Cardiology, 2014.
55. H. Dweep, C. Sticht, P. Pandey, and N. Gretz, "MiRWalk-database: prediction of possible miRNA binding sites by walking the genes of three genomes," Journal of Biomedical Informatics, vol. 44, no. 5, pp. 839-847, 2011.
56. S. S. C. Chim, T. K. F. Shing, E. C. W. Hung, et al., "Detection and characterization of placental microRNAs in maternal plasma," Clinical Chemistry, vol. 54, no. 3, pp. 482-490, 2008.
57. C. H. Lawrie, S. Gal, H. M. Dunlop, et al., "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma," British Journal of Haematology, vol. 141, no. 5, pp. 672-675, 2008.
58. M. A. Cortez and G. A. Calin, "MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases," ExpertOpinion on BiologicalTherapy, vol. 9, no. 6, pp. 703-711, 2009.
59. S. P. Romaine, M. Tomaszewski, G. Condorelli, and N. J. Samani, "MicroRNAs in cardiovascular disease: an introduction for clinicians," Heart, vol. 101, no. 12, pp. 921-928, 2015.
60. L. Tan, J.-T. Yu, and L. Tan, "Causes and consequences of microRNA dysregulation in neurodegenerative diseases," Molecular Neurobiology, vol. 51, no. 3, pp. 1249-1262, 2015.
61. G. S. Mack, "MicroRNA gets down to business," Nature Biotechnology, vol. 25, no. 6, pp. 631-638, 2007.
62. miRBase, 21st version, http://www.mirbase.org/.
63. M. R. Friedlander, E. Lizano, A. J. S. Houben, et al., "Evidence for the biogenesis ofmore than 1, 000 novel human microRNAs," Genome Biology, vol. 15, no. 4, article R57, 2014.
64. C. C. Pritchard, H. H. Cheng, and M. Tewari, "MicroRNA profiling: approaches and considerations," Nature Reviews Genetics, vol. 13, no. 5, pp. 358-369, 2012.
65. A. Zampetaki, S. Kiechl, I. Drozdov, et al., "Plasma MicroRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes," Circulation Research, vol. 107, no. 6, pp. 810-817, 2010.
66. F. J. Ortega, J. M. Mercader, J. M. Moreno-Navarrete, et al., "Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization," Diabetes Care, vol. 37, no. 5, pp. 1375-1383, 2014.
67. Y. Liu, G. Gao, C. Yang, et al., "The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetesmellitus," International Journal of Molecular Sciences, vol. 15, no. 6, pp. 10567-10577, 2014.
68. D. S. Karolina, A. Armugam, S. Tavintharan, et al., "MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus," PLoS ONE, vol. 6, no. 8, Article ID e22839, 2011.
69. N. Pescador, M. Perez-Barba, J. M. Ibarra, A. Corbatón, M. T. Martinez-Larrad, and M. Serrano-Rios, "Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers," PLoS ONE, vol. 8, no. 10, Article ID e77251, 2013.
70. X. Wang, J. Sundquist, B. Zöller, et al., "Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2," PLoS ONE, vol. 9, no. 1, Article ID e86792, 2014.
71. R. Bijkerk, J. M. Duijs, M. Khairoun, et al., "Circulating MicroRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation," American Journal of Transplantation, vol. 15, no. 4, pp. 1081-1090, 2015.
72. M. A. Bellinger, J. S. Bean, M. A. Rader, et al., "Concordant changes of plasma and kidney microRNA in the early stages of acute kidney injury: time course in a mouse model of bilateral renal ischemia-reperfusion," PLoS ONE, vol. 9, no. 4, Article ID e93297, 2014.
73. S. S. Acharya, W. Fendler, J. Watson, et al., "Serum microRNAs are early indicators of survival after radiation-induced hematopoietic injury," Science TranslationalMedicine, vol. 7, no. 287, Article ID 287ra269, 2015.
74. P. Rotkrua, S. Shimada, K. Mogushi, Y. Akiyama, H. Tanaka, and Y. Yuasa, "Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model," British Journal of Cancer, vol. 108, no. 4, pp. 932-940, 2013.
75. S. D. Calligaris, M. Lecanda, F. Solis, et al., "Mice longterm high-fat diet feeding recapitulates human cardiovascular alterations: an animalmodel to study the early phases of diabetic cardiomyopathy," PLoS ONE, vol. 8, no. 4, Article ID e60931, 2013.
76. L. Moldovan, K. E. Batte, J. Trgovcich, J. Wisler, C. B. Marsh, and M. Piper, "Methodological challenges in utilizing miRNAs as circulating biomarkers," Journal of Cellular and Molecular Medicine, vol. 18, no. 3, pp. 371-390, 2014.
77. B. Yang, H. Lin, J. Xiao, et al., "The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2," Nature Medicine, vol. 13, no. 4, pp. 486-491, 2007.
78. J. Xiao, X. Luo, H. Lin, et al., "MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts," The Journal of Biological Chemistry, vol. 282, pp. 12363-12367, 2007.
79. L. Kong, J. Zhu, W. Han, et al., "Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study," Acta Diabetologica, vol. 48, no. 1, pp. 61-69, 2011.
80. E. van Rooij, L. B. Sutherland, N. Liu, et al., "A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18255-18260, 2006.
81. Z. Lu, Y. Li, A. Takwi, et al., "miR-301a as anNF-kappaBactivator in pancreatic cancer cells," The EMBO Journal, vol. 30, no. 1, pp. 57-67, 2011.
82. B. K. Panama, D. Latour-Villamil, G. P. Farman, et al., "Nuclear factor κb downregulates the transient outward potassium current Ito, f through control of KChIP2 expression," Circulation Research, vol. 108, no. 5, pp. 537-543, 2011.
83. A. K. Pandey, P. Agarwal, K. Kaur, and M. Datta, "MicroRNAs in diabetes: tiny players in big disease," Cellular Physiology and Biochemistry, vol. 23, no. 4-6, pp. 221-232, 2009.
84. S. Greco, P. Fasanaro, S. Castelvecchio, et al., "MicroRNA dysregulation in diabetic ischemic heart failure patients," Diabetes, vol. 61, no. 6, pp. 1633-1641, 2012.
85. X. Zhong, A. C. K. Chung, H. Y. Chen, et al., "MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes," Diabetologia, vol. 56, no. 3, pp. 663-674, 2013.
86. J. Osipova, D.-C. Fischer, S. Dangwal, et al., "Diabetes-associated MicroRNAs in pediatric patients with type 1 diabetesmellitus: a cross-sectional cohort study," Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 9, pp. E1661-E1665, 2014.
87. C. Higuchi, A. Nakatsuka, J. Eguchi, et al., "Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes," Metabolism, vol. 64, no. 4, pp. 489-497, 2015.